Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daptomycin intravenous - Viatris/Avecho Biotechnology

Next Previous
Drug Profile

Daptomycin intravenous - Viatris/Avecho Biotechnology

Alternative Names: TPM®/Daptomycin Lyophilized Powder for IV Injection; TPM® Daptomycin

Latest Information Update: 28 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Phosphagenics
  • Developer Avecho Biotechnology; Viatris Inc
  • Class Antibacterials; Cyclic peptides; Lipopeptides; Peptide antibiotics; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Bacteraemia; Skin and soft tissue infections

Most Recent Events

  • 28 Mar 2022 No recent reports of development identified for preclinical development in Skin-and-soft-tissue-infections in USA (IV, Injection)
  • 24 Mar 2020 Preclinical development in Skin-and-soft-tissue-infections is ongoing in USA (IV, Injection) (Phosphagenics pipeline, March 2020)
  • 28 Dec 2018 No development reported for Preclinical for Bacteraemia in USA (IV, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top